Redcliffe Labs aims to scale up operations, go public in 2025-26: Founder

The company, which commenced operations in 2018, has 81 laboratories and over 2,000 collection centres in small cities and towns

pharma
Photo: Bloomberg
Press Trust of India New Delhi
2 min read Last Updated : Aug 14 2023 | 6:27 PM IST

Don't want to miss the best from Business Standard?

Diagnostics platform Redcliffe Labs is looking to scale up its operations with 250 laboratories and 10,000 collection centres by 2025 and plans to go public in 2025-26, according to its founder and Managing Director Dheeraj Jain.

The company, which commenced operations in 2018, has 81 laboratories and over 2,000 collection centres in small cities and towns.

Redcliffe Labs, which has raised USD 80 million so far, has set an ambitious target of having 700 laboratories and 25,000 collection centres by 2027-28.

In an interaction with PTI, Jain said the short-term target is to have 10,000 collection centres and 250 laboratories by 2025.

He noted that the majority of the expansion will be in Tier II, Tier III and Tier IV locations across states like Uttar Pradesh, Madhya Pradesh, Rajasthan, Bihar, Jharkhand and Chattisgarh which have less developed infrastructure for diagnostics.

"We are also looking at simplifying the reports with AI technology, going deeper in states where we are present now and also strengthening our presence in Maharashtra and Gujarat," Jain said.

The company will also look at expanding specialized testing packages.

Jain said the company is well covered in terms of capital for now but may look at another round of funding by the end of this year or next year to take care of acquisitions to expand the radiology vertical.

Redcliffe, which generates revenues of around Rs 500 crore per annum, has invested Rs 450 crore between 2020-2023 to create the required infrastructures in terms of collection centres, laboratories and manpower.

It currently employs 3,000 people..

Jain noted that the company will probably break even later this year.

"In 2025-26 we may go public. It will help us to scale up the business," he noted.

Currently the promoter group has around 30 per cent stake in the diagnostics firm. Jain said there is immense potential in the diagnostics space with the segment doubling in the country every 4.5 years.

He noted that the focus on technology-enabled processes would help the company to scale up going ahead as well.

Redcliffe Labs has collaborated with Abbott India to introduce clinical decision support (CDS) also known as AlinIQ, powered by various proprietary technologies including Big Data Engines and Artificial Intelligence (AI). The initiative aims to enhance patient care and convenience.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :DiagnosticsIPOsMarket

First Published: Aug 13 2023 | 11:42 AM IST

Next Story